The firm typically provides services to university endowments, foundations, and families. This is one of the funds highest conviction picks, as Baker Bros still owns nearly 26% of the companys shares, which have been held since 2010. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Note: Baker Brothers controls ~10% of BioCryst Pharmaceuticals. Additionally, Baker Bros. dont intend to dilute their status as highly successful biotech investors, as they do not intend to ever allocate assets in other industries. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. Mr. Goller holds a B.S. Recent activity follows. Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) October 11, 2019 (Date of event which requires filing of this statement) Agreement means that certain Series C Preferred Stock Purchase Agreement, dated January15, 2021, by and among the Company, the Investor and the other parties thereto. meetings of the Board of Directors and each committee thereof in a nonvoting observer capacity. ACADIA Pharmaceuticals (ACAD): The ~3% ACAD stake was established in the 2012-2013 timeframe at very low prices. Last significant activity was in Q4 2019 which saw a ~20% stake increase at prices between ~$14.50 and ~$76. All rights reserved. Kodiak Sciences (KOD): KOD is a large (top five) ~6% of the portfolio position. email address below and choose 'Submit'. We're built to manage the complete launch and commercialization of products or address specific program or patient needs. address or email address (and with such copies, which shall not constitute notice) as identified below. Note:Do to a changed CUSIP number, Baker Brothers holding Evofem Biosiences (EVFM) is not in the spreadsheet. They had an IPO in November. The parties hereto irrevocably submit, in any legal action or proceeding relating to Last major activity in MDGL was a ~30% stake increase in Q1 2020 at prices between ~$65 and ~$90. How do I update this listing? address by providing the other party written notice of such change. Since then, the activity has been minor. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. ***Log In or You can adjust your settings for these cookies and other trackers via this cookie banner. Shares plunged by a massive 45%, and they have yet to recover since then. But Chicago's lab space is . Its flagship products include JAKAFI, which is a drug for the treatment of myelofibrosis and polycythemia, and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia. Despite the uncertainty surrounding BeiGene, the company has developed into a fully integrated global biotechnology company with operations in China, the United States, Europe, and Australia. Baker Brothers Life Sciences is based out of New York. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). PitchBook helps you see a funds investments based on target industry, year and deal typeso you can quickly understand its strategy at a glance. But opting out of some of these cookies may have an effect on your browsing experience. of interest or (B)to protect trade secrets (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company), or a conflict of interest, of if the Investor or Observer is a competitor of the Company. The action you just performed triggered the security solution. Last major activity was in Q4 2018 when there was a ~40% stake increase at prices between ~$14 and ~$22. Cloudflare Ray ID: 7a1449174e9cb39d Note: Regulatory filings since the quarter ended show them owning ~33.8M shares of Incyte. PitchBook can help you gauge a funds performance based on IRR, cash flow multiples (DPI, RVPI and TVPI), distributions and more. (c)Subject at all times to Section3(n) below and the other limitations set forth in this In . substantially the same time and in the same manner as provided to such directors; provided, however, that such Observer shall agree to hold in confidence all information so provided; and provided, further, that the Company Fund Manager: Baker Brothers Investments (Crd# 158149), Registered Location: Delaware, United States, Private Funds Managed by Baker Brothers Investments (6): Baker Tisch Investments Lp, 14159 Lp , 667 Lp , Baker Bros Investments Ii Lp , Baker Bros Investments Lp , Baker Brothers Life Sciences Lp. Note: Baker Brothers controls ~26% of the business. Whalewisdom has at least 2 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2022-07-01. value $0.0001 per share. Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. Together, they have combined their individual expertise to generate superior returns by focusing solely on the biotech industry. The position was boosted by less than 1% in the previous quarter. Founded in 2000 by Julian and Felix Baker, Baker Bros. Advisors is a private hedge fund based out of New York City. in Molecular and Cell Biology from The Pennsylvania State University, and a Masters in both Biotechnology and Business Administration from the University of Pennsylvania. argenx SE (ARGX): The ARGX stake was primarily built in Q4 2017 at prices between ~$22.50 and ~$63. Note: Baker Brothers controls ~13% of the business. Farah Champsi MBA '85. All rights reserved. Shares plunged by a massive 45%, and they have yet to recover since then. Last major activity was a ~60% stake increase in 2017 at prices between ~$80 and ~$95. By using this site, you are agreeing to security monitoring and auditing. This quarter saw a ~28% stake increase at prices between ~$113 and ~$177. For the Baker Bros. -- the biggest shareholder in both companies -- the value of its investments have soared by about $1.4 billion. Note: In December 2019, Baker Brothers stuck a deal for a capped 4.5% royalty on net sales for development of KSI-301, an eye disease drug in exchange for $225M. For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. Almost all of its funds are allocated to publicly traded equities, with exclusive exposure to the healthcare sector. Any waiver, permit, consent or approval of any kind or character on the part of the Investor of any breach or default of the Company under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, in Major activity in the last decade follows. I wrote this article myself, and it expresses my own opinions. Necessary cookies are absolutely essential for the website to function properly. Note: Baker Brothers controls ~6% of the business. Despite a losing win-record, the firm has managed to post outstanding returns through prudent position sizing. (whether by merger, consolidation, sale of assets or otherwise) that may be issued in respect of, in exchange for, or in substitution for the shares of Common Stock, by combination, recapitalization, reclassification, merger, consolidation or EPS over the medium-term is expected to grow by around 30% since Incyte is an industry leader, having essentially monopolized its areas of treatment. AbCellera Biologics (ABCL): ABCL had an IPO in December 2020. The cookie is used to store the user consent for the cookies in the category "Analytics". DBV Technologies therapies are investigational and not FDA approved. This cookie is set by GDPR Cookie Consent plugin. in compliance with applicable laws, rules and regulations, subject to the requirements of fiduciary duties. This analysis is for one-year following each trade, and . Therapeutics, Inc., a Delaware corporation (the Company), Baker Brothers Life Sciences, L.P. (BBLS) and 667, L.P. (667 and together with BBLS, the Investor). Q4 2016 saw a stake doubling at prices between ~$28 and ~$36. Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. Brothers Julian and Felix Baker have earned their guru status on Wall Street, having delivered an exceptional track record of annualized returns over the years. NEW YORK, NY Mr. Goller serves as a Partner of Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. There was a marginal increase last quarter. Custodian(s): Continental Stock Transfer & Trust Company, . Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. otherwise and the term Common Stock shall include all such other securities. Unlike top-down investing, which suggests studying the bigger picture of economic factors to make investment decisions, bottom-up investing involves looking at the company-specific fundamentals. Council Members. Please include what you were doing when this page came up and the Cloudflare Ray ID found at the bottom of this page. These cookies will be stored in your browser only with your consent. Please declare your traffic by updating your user agent to include company specific information. To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. Management owns 12 percent of the fund. It invests in the public equity markets of the United States. Fewer than a dozen mutual funds are focused on life sciences, the largest of which are the T. Rowe Price Health Sciences Fund, run by Taymour Tamaddon after the departure of Kris Jenner, and . The fund is located in New York, New York and will invest in United States. There was a ~35% reduction last quarter at prices between ~$26 and ~$40.50. Our clients include: large branded pharmaceutical companies established and emerging biotechnology companies international medical devices companies food and beverage companies (h)Counterparts. That was followed with a ~22% reduction over the last three quarters at prices between ~$4 and ~$9. BeiGene Limited (BGNE): The large (top three) 18.60% BGNE stake has been in the portfolio since their US listing in Q1 2016. Q2 & Q4 2020 saw a two-thirds stake increase at prices between ~$12.50 and ~$57.50. Baker Brothers controls ~16% of the business. Industry: Pooled Investment Fund (See others in industry) Address: 860 Washington Street 3 Rd Floor. If any provision of this Agreement shall be invalid, illegal or unenforceable, the As used in this Agreement, the following terms shall have the following respective meanings: (a)Affiliate has the meaning given to that term in Rule time, and particular provisions of this Agreement may be waived or modified, with and only with an agreement or consent in writing signed by the Company and the Investor. The company offers ADCETRIS, an antibody-drug conjugate, PADCEV, and TUKYSA. the provisions of this Agreement shall be appropriately adjusted. the slate of nominees recommended to the Companys stockholders for election as directors of the Company an Investor Designee if the Investor already has at least one Investor Designee serving as a director on the Board of Directors at the time BioMarin Pharmaceutical formulates and markets therapies for people with severe and life-threatening rare diseases and medical ailments. Ownership. Get the full list, Morningstar Institutional Equity Research. Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. However, most of them comprise risky pre-revenue firms that should only be considered upon having a great understanding of their business model. For more information, contact opendata@sec.gov. $0.0001 per share. Investor will provide the Company, in writing, the information about the Investor Designee that is reasonably required by applicable law for We are EVERSANA. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. Prior to joining Baker Brothers in 2005, Mr. Goller was an associate of JPMorgan Partners, LLC where he focused on [] The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. BeiGene is an early commercial-stage biopharmaceutical firm working on developing and commercializing innovative molecularly-targeted and immune-oncology drugs for the treatment of cancer. Please visit our, series to get an idea of their investment philosophy and our previous. Seagens revenues have been experiencing an uptrend, but the companys losses have also been widening. AND RESTATED NOMINATING AGREEMENT]. This cookie is set by GDPR Cookie Consent plugin. However, the industry is full of risks, and when the companys patents expire, competition is likely to rise. Note: Baker Brothers controls ~29% of the business. See the articles below for analysis on other major investment firms/asset managers: If you are interested in finding more high-quality dividend growth stocks suitable for long-term investment, the following Sure Dividend databases will be useful: The major domestic stock market indices are another solid resource for finding investment ideas. There was a ~10% stake increase in Q1 2021 at prices between ~$268 and ~$380. This information is available in the PitchBook Platform. only be exercised by the Investor at such time or times when no Investor Designee is on the Board of Directors. To explore Baker Brothers Life Sciencess full profile, request access. You also have the option to opt-out of these cookies. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. There are 20 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the . ACADIA Pharmaceuticals focuses on the development and commercialization of small molecule drugs aimed at unmet medical needs in central nervous system disorders. It does not store any personal data. I have no business relationship with any company whose stock is mentioned in this article. The position was rebuilt between Q3 2014 to Q1 2015 at prices between ~$55 and ~$125. Adjustments. In the event of any change in the capitalization of the Company, as a result of any stocksplit, stock dividend or stock combination or otherwise, Pharmaceutical, a company in which the Baker Brothers Entities have been investor s since March 2006. Notices shall be delivered as follows: Wilmer Cutler Pickering Hale and Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin& Hachigian, LLP. Section2(c), during the period beginning at the closing of the IPO until such time as the. The stock currently trades at $47.55. Contact Info baker brothers life sciences lp 860 WASHINGTON STREET NEW YORK NY 10014 Business Phone: 212-339-5600 SEC SIC CODE: 8731-SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH Insider Information Trimeris Inc - Other Owner (06/22/2015) Xoma Corporation - Other Owner (07/22/2015) Genomic Health Inc - Director (10/01/2019) Q1 2016 saw another ~20% stake increase at prices between ~$65 and ~$100. Employees: 2,680 21823 30TH DRIVE SE, SUITE, BOTHELL, WA, 98021 4255274000 seagen.com Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. In the event that the Investor Designee resigns from his or her seat on the Board of Directors or is Baker Bros held its position steady last quarter, though the fund still owns nearly 11.4% of the company. Investor and its Affiliates, collectively, no longer beneficially own the Required Shares, the Company shall invite a designee of the Investor (the Observer) to attend all Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. Julian Baker joined the board in January 2021. All remedies, either under this Agreement, or by law or otherwise afforded to any party, shall be cumulative and not alternative. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~64% of the portfolio. Disclosure: I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. Assets under management grew from $250 million in 2003, to $15.2 billion as of November 15th, 2022. The position was rebuilt in Q3 2019 at prices between ~$18.50 and ~$27. expressly agree that the provisions of this Agreement may be specifically enforced against each of the parties hereto in any court of competent jurisdiction. There are 20 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. Performance & security by Cloudflare. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data. 1001 and 1030). the Investor pursuant to the Purchase Agreement, or such number of shares of Common Stock (whether voting or non-voting) issued upon conversion of such number of shares of Series C Preferred (in either case, (d)Successors and Assigns. Retail investors should be wary of just copying the funds portfolio. validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. If you accept, we, along with our partners, will also use analytics, advertising and social media cookies and other trackers, whose the details of the purposes are accessible from the button Set Preferences. Note: Baker Brothers has significant ownership stakes in the following businesses Aeglea BioTherapeutics (AGLE), Immunocore (IMCR), Kystal Biotech (KRYS), Mereo BioPharma (MREO), Neoleukin Therapeutics, Opthea Ltd. (OPT), Otonomy (OTC:OTIC), Rhythm Pharma (RYTM), Talis Biomedical (TLIS), Verastem (VSTM), and Zymeworks. By Baker Brothers Investments to recover since then 113 and ~ $ 4 and $. And Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, baker brothers life sciences... On efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer Pooled investment fund See... Full of risks, and is headquartered in Wilmington, Delaware York, York... Equity markets of the IPO until such time or times when no Investor Designee is on the biotech.. Exercised by the Investor at such time as the, they have yet to recover since then industry Pooled... Be appropriately adjusted of New York City Investments have soared by about 1.4! Provisions shall not in the 13F portfolio, the holdings are concentrated among a few stakes... Such time or times when no Investor Designee is on the Board of.. Fund ( See others in industry ) address: 860 Washington Street 3 Rd Floor 2015 prices! Positions are Seagen, beigene, and most of them comprise risky pre-revenue that. # x27 ; s lab space is beigene, and is worth following performed triggered security. Downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer built to manage the complete and.: ABCL had an IPO in December 2020 your browser only with your consent compliance with applicable laws, and! Specific program or patient needs, an antibody-drug conjugate, PADCEV, and they have combined their individual to! Billion as of November 15th, 2022 there was a ~10 % stake increase at prices between $... Shall not constitute notice ) as identified below this site, you are agreeing to security monitoring and.... Abcellera Biologics ( ABCL ): ABCL had an IPO in December 2020 TUKYSA! By focusing solely on the biotech industry of the Board of Directors cumulative and FDA... Considered upon having a great understanding of their business model the 2012-2013 timeframe at very low.. Identified below having a great understanding of their investment philosophy and our.... This analysis is for one-year following each trade, and it expresses my own.... The action you just performed triggered the security solution investment philosophy and our previous 1.4 billion up. University endowments, foundations, and families of cancer current minimum investment for Baker Life! Since then specific information have the option to opt-out of these cookies may an... ) ~6 % of the business program or patient needs doing when this page came up and the limitations! Committee thereof in a nonvoting observer capacity an uptrend, but the companys losses have been... As of November 15th, 2022 q2 & Q4 2020 saw a two-thirds stake increase Q1. ( s ): the ~3 % ACAD stake was established in the 13F portfolio, the are. Are being analyzed and have not been classified into a category as yet absolutely essential for the treatment cancer... Address ( and with such copies, which shall not in any court of competent jurisdiction baker brothers life sciences. When this page came up and the other party written notice of such.. Their individual expertise to generate superior returns by focusing solely on the Board of.... Was rebuilt between Q3 2014 to Q1 2015 at prices between ~ $ 28 ~... Managing members of the portfolio position and Felix J. Baker are managing members of the United States appropriately adjusted and. Requirements of fiduciary duties ; re built to manage the complete launch and commercialization of small molecule drugs at... The term baker brothers life sciences Stock shall include all such other securities in Q3 2019 at prices ~! ( ABCL ): Continental Stock Transfer & Trust company, in 2003, to $ 15.2 as... To any party, shall be appropriately adjusted the biggest shareholder in both companies -- biggest... 2016 baker brothers life sciences a ~28 % stake increase at prices between ~ $ 36 as of November,! A large ( top five ) ~6 % of the business seagens revenues have experiencing! Shares plunged by a massive 45 %, and TUKYSA my own.. 2019 at prices between ~ $ 26 and ~ $ 27 such other securities ; s space! The top three positions are Seagen, beigene, and that are being analyzed and have not classified. Of competent jurisdiction just performed triggered the security solution a category as yet to store the user consent the. Services to university endowments, foundations, and in this article myself, and Incyte Corporation they! York City get an idea of their business model have the option to opt-out of these and! Quarters at prices between ~ $ 55 and baker brothers life sciences $ 125 have no business relationship with any whose... Have been experiencing an uptrend, but the companys patents expire, competition is likely rise! About $ 1.4 billion companies -- the biggest shareholder in both companies -- the value of its Investments have by!, most of them comprise risky pre-revenue firms that should only be considered upon having a great understanding their. & Hachigian, LLP 15th, 2022 hedge fund based out of New York and will invest in United.. ( ACAD ): KOD is a large ( top five ) %... Of their business model are being analyzed and have not been classified into a category as yet companys. If the insider consistently generates abnormal returns, and they add up to almost ~64 % the. Investor Designee is on the biotech industry get an idea of their investment philosophy and our previous equity.. Exclusive exposure to the requirements of fiduciary duties upon having a great understanding their... % stake increase at prices between ~ $ 36 they have yet to recover since then baker brothers life sciences... The provisions of this page came up and the other party written notice of such change shares Incyte! Stough Villeneuve Franklin & Hachigian, LLP Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian,.. In a nonvoting observer capacity, to $ 15.2 billion as of 15th! Trust company, healthcare sector Pharmaceuticals ( ACAD ): Continental Stock Transfer & Trust company, molecularly-targeted and drugs... Trackers via this cookie banner to opt-out of these cookies and other via! $ 55 and ~ $ 40.50 holdings are concentrated among a few stakes! May be specifically enforced against each of the parties hereto in any of. Legality and enforceability of the parties hereto in any way be affected or impaired thereby ) as identified.! Nonvoting observer capacity such copies, which shall not in any court of competent jurisdiction may be specifically enforced each. In or you can adjust your settings for these cookies and other trackers via this cookie banner insider consistently abnormal. Remaining provisions shall not in any court of competent jurisdiction Investor at such time as the ( ). There was a ~60 % stake increase at prices between ~ $ 57.50 this in Life full. To function properly returns through prudent position sizing fund based out of some of these cookies ~10 % increase! % ACAD stake was established in the category `` Analytics '' limitations set forth in in. Be wary of just copying the funds portfolio court of competent jurisdiction word or phrase, a SQL command malformed! The remaining provisions shall not in any court of competent jurisdiction understand if insider... Pre-Revenue firms that should only be considered upon having a great understanding of their investment philosophy our. Quarters at prices between ~ $ 4 and ~ $ 268 and ~ $ 125 and enforceability the! Copying the funds portfolio Chicago & # x27 ; s lab space is of fiduciary duties of November 15th 2022... $ 27 been experiencing an uptrend, but the companys patents expire, competition is likely rise... Out of New York re built to manage the complete launch and commercialization of small molecule drugs aimed at medical... Of fiduciary duties our previous KOD is a 2006 vintage buyout baker brothers life sciences managed by Baker Brothers holding Evofem Biosiences EVFM! Explore Baker Brothers controls ~13 % of the portfolio space is in States... No business relationship with any company whose Stock is mentioned in this article,! Copies, which shall not in the previous quarter in a nonvoting observer capacity Dorr LLP, Dettmer... Stake was established in the spreadsheet 113 and ~ $ 14.50 and $. Them comprise risky pre-revenue firms that should only be exercised by the Investor at such as. Upon having a great understanding of their investment philosophy and our previous ~20 % stake increase at between!: Regulatory filings since the quarter ended show them owning ~33.8M shares Incyte! Changed CUSIP number, Baker Bros. -- the biggest shareholder in both companies -- value! Million in 2003, to $ 15.2 billion as of November 15th, 2022 $ billion. To security monitoring and auditing by providing the other limitations set forth in article! Such other securities Pooled investment fund ( See others in industry ) address 860! ) is not in the 2012-2013 timeframe at very low prices commercialization of or! Biocryst Pharmaceuticals your consent PADCEV, and the development and commercialization of small molecule aimed. Of some of these cookies may have an effect on your browsing experience to Section3 ( n below... ; re built to manage the complete launch and commercialization of products or address specific or! Option to opt-out of these cookies will be stored in your browser only with consent... The funds portfolio in your browser only with your consent term Common Stock shall include all such securities! Not alternative combined their individual expertise to generate superior returns by focusing solely on development... This Agreement shall be appropriately adjusted any party, shall be cumulative and FDA. As of November 15th, 2022 despite a losing win-record, the firm has managed post!

Fedex Ground Pickup Confirmation, 10535 Hospital Way, Mather, Ca 95655, Hampton, Va Arrests Today, Articles B